Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Depression dose study pulled before starting

NCT ID NCT05210153

Knowledge-focused Sponsor: University of Belgrade Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if measuring sertraline (Zoloft) levels in the blood and checking a specific gene (CYP2C19) could help doctors give the right dose to people with major depression. The goal was to reduce side effects and improve treatment. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sertraline (Zoloft)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Jul 2020

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population includes outpatients suffering from Major Depressive disorder who are previously untreated, and are seeking medical help for the first time.

Ages

18 to 60 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed Major Depressive Disorder * Starting monotherapy with sertraline * Signed written informed consent Exclusion Criteria: * Patient's requests to leave the study * Patients who had taken sertraline before * Dementia * Severe liver function impairment (abnormal AST/ALT ratio) * Severe kidney function impairment (abnormal creatinine clearance) * History of drug addiction (sporadic use is permitted) * Suicide risk * Patients who are taking strong CYP2C19 inhibitors * Severe adverse drug reaction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder, major are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depressive disorder, major

Contacts and locations

Locations

  • Clinical Centre of Serbia

    Belgrade, 11000, Serbia

  • Institute of Mental Health

    Belgrade, 11000, Serbia

  • Military Medical Academy

    Belgrade, 11000, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.